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Objectives: To describe the incidence, severity and progression of proteinuria over the first 6 months of 
masitinib treatment in tumour-bearing dogs without pre-existing proteinuria. To describe the effect of 
treatment on urine protein:creatinine and renal parameters in patients with pre-existing proteinuria.
Materials and MethOds: Records were reviewed from patients receiving masitinib for neoplasms 
between June 1, 2010, and May 5, 2019. Patients without pre-treatment and at least one urine 
protein:creatinine after ≥7 days treatment were excluded. Signalment, tumours and concurrent diseas-
es, treatments, haematology, biochemistry and urinalysis results before, during and after treatment for 
up to 202 days were collected. Patient visits were grouped into six timepoints for analysis.
results: Twenty-eight dogs were included. Eighteen percent of dogs non-proteinuric at baseline 
(four of 22) developed proteinuria during treatment, all within 1 month of treatment initiation. One 
dog developed hypoalbuminaemia, none developed oedema or ascites, azotaemia or were euthana-
sed/died due to proteinuria. Masitinib was immediately discontinued in both dogs in which urine 
protein:creatinine greater than 2.0 was detected and in both, proteinuria improved.
Six dogs with pre-treatment proteinuria were treated with masitinib, significant worsening of protein-
uria did not occur. Neither azotaemia nor severe hypoalbuminaemia occurred.
clinical significance: Proteinuria, when it occurs, tends to develop within 1 month of masitinib com-
mencement and may progress rapidly. Weekly proteinuria monitoring should be considered for the first 
month and a urine protein:creatinine greater than 0.5 should prompt reassessment within 1 week. Ma-
sitinib treatment can be considered in patients with pre-treatment proteinuria and does not inevitably 
cause worsening of proteinuria.
The study was granted ethical approval by the local committee.
INTRODUCTION
Masitinib (Masivet; AB Science) is a tyrosine kinase inhibitor (TKI) 
licensed to treat canine non-resectable grade II or III mast cell 
tumours (MCT) with a confirmed mutation of the tyrosine kinase 
(TK) receptor, KIT. Off-licence use for other MCT, malignant 
melanoma (MM), epitheliotropic lymphoma (EL) and for atopic 
dermatitis management has also been reported (Hahn et al. 2008, 
AB Science 2009, Cadot et al. 2011, Devine & Polzin 2016, Holt-
ermann et al. 2016, Miller et al. 2016, Giuliano & Dobson 2020).
Tyrosine kinases selectively phosphorylate other proteins, 
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pathways. Masitinib binds to specific TK receptors (includ-
ing stem cell factor receptor (KIT)) inhibiting their function 
(Dubreuil et al.  2009). As TK receptors are ubiquitous in the 
body, their inhibition can have undesirable effects on normal tis-
sue causing toxicity. Although normally well tolerated, gastro-
intestinal, haematological, hepatic and renal adverse events are 
reported (Hahn et al. 2008; Smrkovski et al. 2015).
Three case reports have documented development of marked 
proteinuria and severe hypoalbuminaemia in dogs receiving 
masitinib (Sum et al. 2010, Brown et al. 2013, Devine & Pol-
zin 2016). Two also subsequently developed acute kidney injury, 
one of which was ultimately euthanased. Dogs receiving masi-
tinib have a documented incidence of proteinuria of 16 to 23% 
but not all develop severe consequences (Cadot et al.  2011, 
Smrkovski et al.  2015). The masitinib datasheet stipulates that 
monthly urine dipstick monitoring should be performed, if pro-
teinuria develops it should be quantified and treatment should be 
temporarily discontinued if the urine protein to creatinine ratio 
(UP:C) exceeds 2.0 (AB Science  2009). The studies reporting 
proteinuria with masitinib give limited information on the sever-
ity, timing of development, progression and outcome in affected 
dogs. A better understanding of the development and course of 
proteinuria is needed.
Normally, small amounts of protein pass through the renal 
glomerular filtration barrier (GFB) and are reabsorbed in the 
proximal tubules, therefore only small amounts of protein are 
detected in urine. When UP:C exceeds 0.5, significant protein-
uria is present (Harley & Langston 2012). Proteinuria may be 
pre-renal, renal or post-renal. Pre-renal proteinuria occurs when 
large amounts of low molecular weight plasma proteins are pres-
ent and are filtered, overwhelming the proximal tubule’s resorp-
tive capacity (e.g. haemoglobinuria). Post-renal proteinuria 
occurs when protein enters urine after the renal pelvis (e.g. cysti-
tis). Renal proteinuria may be either physiological and transient 
(e.g. fever, seizures or intense exercise) or pathological. Pathologi-
cal renal proteinuria can be either glomerular or tubular in ori-
gin. Glomerular proteinuria implies an alteration in structure or 
function of the GFB, whilst tubular proteinuria can occur either 
due to defects in tubular resorptive mechanisms (e.g. Fanconi 
syndrome) or through a reduction in nephron numbers or altered 
haemodynamics secondary to tubulointerstitial inflammation. 
The greater the magnitude of renal proteinuria, the more likely 
the underlying aetiology is glomerular in origin, particularly if 
the UP:C is greater than two (Lees et al. 2005).
Proteinuria associated with masitinib treatment is believed to 
be glomerular. In two cases in which renal tissue was collected, 
negligible glomerular changes were seen on light microscopy, but 
global effacement of podocyte foot processes was found on elec-
tron microscopy, consistent with minimal change disease (Sum 
et al. 2010, Brown et al. 2013). The mechanism by which this 
happens is unclear. In addition to inhibition of KIT, in-vitro inhi-
bition of platelet-derived growth factor receptor (PDGFR) α and 
β, Lyn kinase and fibroblast growth factor receptor 3 have been 
reported with masitinib (Dubreuil et al. 2009). Although normal 
glomerular cells do not express KIT, glomerular cells of primates 
do express PDGFRs (Alpers et al.  1993, Miliaras et al.  2004). 
This may also be true in dogs and inhibition of this receptor 
may result in reduced podocyte integrity in susceptible animals 
(Sum et al.  2010). Alternatively, proteinuria may be mediated 
through inhibition of another receptor or the development of 
hypertension. Hypertension is a recognised complication of 
human TKI use (Chu et al. 2007, Azizi et al. 2008) and increases 
in canine systolic blood pressure (SBP) were reported with TKI 
administration (toceranib phosphate) (Tjostheim et al.  2016). 
However, in two case reports of masitinib-associated proteinuria, 
hypertension was not documented (Sum et al. 2010, Devine & 
Polzin 2016). Possibly, masitinib’s more selective TK inhibition 
profile (specifically a lack of vascular endothelial growth factor 
receptor (VEGFR) inhibition) means hypertension does not 
occur (Dubreuil et al. 2009).
The datasheet stipulates that masitinib should not be admin-
istered to dogs with a pre-treatment UP:C exceeding 2.0 (AB 
Science  2009). Its use in dogs with pre-existing proteinuria 
(UP:C > 0.5) has not been reported. Fifteen percent of dogs pre-
sented to an oncology service were proteinuric at presentation 
(Prudic et al. 2018) but these patients may not have pathologi-
cal renal proteinuria or be predisposed to masitinib-associated 
glomerular pathology. In some dogs, masitinib may be the only 
remaining treatment choice when other options have been 
exhausted. Information reporting masitinib’s effects in protein-
uric dogs is therefore needed.
This study’s aims were to (1) describe the incidence, severity 
and progression of proteinuria over the first 6 months of masi-
tinib treatment in tumour-bearing dogs without pre-existing 
proteinuria and (2) describe the effect of treatment on UP:C and 
renal parameters in dogs with pre-existing proteinuria.
MATERIALS AND METHODS
Clinical records of dogs referred to a university teaching hospi-
tal were retrospectively evaluated. The database was searched for 
all dogs charged the item masitinib between June 1, 2010, and 
May 31, 2019. Dogs were subsequently excluded if they were not 
diagnosed with neoplasia, did not have a urinalysis (including 
UP:C) performed within 1 month before starting masitinib, were 
not treated with masitinib for ≥7 days or did not have follow-up 
urinalysis (including UP:C) after a minimum of 7 days masitinib 
treatment.
Patient information collected is shown in Table  1. The study 
period was defined as the day of masitinib commencement to day 
202. Follow-up information, including date and reason for both 
masitinib discontinuation and for death, was obtained from the 
records or via phone calls to owners or referring veterinary surgeons.
Urinalysis results were only included if they were performed 
at a reference laboratory. At each timepoint, the urine was classi-
fied as non-proteinuric (UP:C ≤ 0.5) or proteinuric (UP:C >0.5). 
Proteinuria was then categorised as likely pre-renal, post-renal, 
physiological renal or pathological renal. Inclusion in several cat-
egories was possible. Pre-renal proteinuria was excluded if; total 
protein was within reference limits and if haematocrit was ≥30%, 
there was less than ‘+’ blood on urine dipstick and if there was 
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no mention of muscle pain or stiffness or creatine kinase was 
normal. Post-renal proteinuria was excluded if no lower urinary 
tract signs (stranguria or dysuria), vaginal or preputial discharge 
or signs of prostatic disease were recorded and if less than five 
white blood cells per high power field (hpf ) or less than “++” 
bacteria were recorded on urine microscopy and urine culture 
(if performed) was negative. Physiological renal proteinuria was 
excluded if there was normothermia and no seizures or intensive 
exercise within 48 hours preceding urine collection. Pathological 
renal proteinuria was assumed possible in all proteinuric cases.
For dogs without proteinuria at baseline, proteinuria was also 
classified using Veterinary cooperative oncology group – com-
mon terminology criteria for adverse events (VCOG-CTAE) 
(VCOG 2016); grade I: UP:C greater than 0.5 but less than 1.0, 
grade II: UP:Cgreater than or equal to 1.0 for less than 14 days 
duration and grade III: UP:C greater than or equal to 1.0 for 
greater than or equal to 14 days.
Statistical analysis
Dogs were grouped based on the presence or absence of pro-
teinuria at baseline. Non-proteinuric dogs were further divided 
based on whether proteinuria developed on treatment during the 
study. Findings were described and analysed at baseline and dur-
ing masitinib treatment for these groups using Microsoft Excel 
(Washington, USA) and Minitab 18 (Minitab Inc., PA, USA). 
Continuous data were expressed as medians and ranges. The 
Kaplan–Meier method with right censoring was used to estimate 
the median duration of masitinib administration. Further statis-
tical analyses were not performed due to the small data set.
RESULTS
Thirty-eight dogs were identified for inclusion. Ten were subse-
quently excluded due to less than 7 days treatment (n=1), no pre-
treatment UP:C within 1 month (n=5) or no UP:C on masitinib 
(n=4). Twenty-eight dogs were included.
Patient parameters are shown in Table 2. Five dogs were being 
treated for EL, one for vulval lymphoma, one for MM and 21 for 
MCT. Four (19.0%) dogs with MCT had subcutaneous tumours 
of which three had less than four mitoses per 10 hpf. Mitotic 
index was unknown in one. For the 17 dogs with cutaneous 
MCTs, the grades were: Patnaik grade I (n=1), Patnaik grade II 
(n=4), Patnaik grade III (n=4), Kiupel low grade (n=1), Kiupel 
high grade (n=6) and unknown (n=1).
Urine was collected a median of 1 day before starting masitinib 
(range: 0 to 22). Twenty-two (79%) dogs were non-proteinuric 
(UP:C < 0.5) and six were proteinuric at baseline.
Of the 104 urine samples included, the methods of urine col-
lection were free catch (n=31), cystocentesis (n=2) and unknown 
(n=71). Ninety-six (92.3%) of urine samples were analysed at the 
university reference laboratory (see Table 3).
Dogs without pre-treatment proteinuria  
(dogs 1 to 22)
In this group, three dogs were treated for EL, one for vulval lym-
phoma, one for MM and 17 for MCT. Of the 17 dogs with MCT, 
three were receiving prednisolone, four were receiving histamine-
1-receptor antagonists, one an histamine-2-receptor antagonist 
and four were receiving both histamine-receptor antagonists. 
The dog with vulval lymphoma was receiving antibiotics. The 
other dogs were not receiving treatment for their tumours. Eight 
dogs had co-morbidities at baseline and six were on treatment for 
these (Dog-8, -9, -11, -12, -18 and -19) (Table 4).
Creatinine was within reference limits in all dogs. Two dogs 
had low albumin (24 and 25 g/L) (reference range (RR): 29 to 
36). Table 2 lists other baseline parameters.
Effect of masitinib treatment
Median masitinib starting dose was 11.66 mg/kg (range: 9.66 to 
13.64). Two dogs had 4-day drug holidays (for hyporexia (dog-1) 
and for hyporexia and vomiting (dog-11)). Six dogs had masi-
tinib dose reductions (10 to 50%). These were for neutropenia 
(five dogs) and thrombocytopenia (one dog).
Median UP:Cs were 0.05, 0.03, 0.07, 0.07, 0.05 and 0.03 at 
T1 to T6 respectively. Four (18.2%) dogs became proteinuric 
during the study period (Table  3). None became azotaemic. 
Table 2 shows parameters for dogs that did and did not develop 
proteinuria within 202 days of masitinib commencement.
Table 1. Patient information collected from the records and collection time points
Background data Signalment, weight, tumour type, grade, date
Baseline data collected at masitinib initiation (denoted T0) Previous treatment details, presence of gross disease, current clinical signs, 
concurrent diseases, concurrent medications (including doses) for neoplasm and 
other comorbidities, date and results of haematology, biochemistry, urinalysis and 
urine cultures (performed within the 21 days preceding masitinib commencement), 
method of urine sample collection, laboratory used for urinalysis, date masitinib 
started, masitinib dose administered
Data collected at:
T1 (7 to 20 days from T0)†
T2 (21 to 34 days from T0)†
T3 (35 to 62 days from T0)†
T4 (63 to 90 days from T0)†
T5 (91 to 146 days from T0)†
T6 (147 to 202 days from T0)†
Appointment date, weight, changes to medication administration or dosing since 
previous visit (including drug holidays), presence of gross disease, current clinical 
signs, dates and results of haematology and biochemistry profiles and urinalysis 
(including UP:C), method of urine sample collection, laboratory used for urinalysis, 
ongoing medication plans
†If a dog had more than one visit during a time-period, the visit closest to the midpoint of the period with a urinalysis was selected. The study period was defined as the day of masitinib 
commencement to day 202
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Effect of masitinib treatment – Dogs that 
developed proteinuria
The maximum UP:C on treatment were 1.06, 1.27, 4.56 and 
8.2 (Fig. 1). None of these dogs had masitinib dose reductions 
or drug holidays. Median time to first detection of proteinuria 
was 14.5 days (range: 13 to 31). In one dog (dog-6), UP:C was 
normal on treatment at a previous visit. Proteinuria was cat-
egorised as pathological renal in two dogs (dog-6 and dog-21) 
and either pathological renal and/or post-renal in 2 (dog-4 and 
dog-8). A urine culture performed 8 days after proteinuria was 
detected in dog-4 was negative despite no antibiotic adminis-
tration in the interim, suggesting bacterial infection as a cause 
of post-renal proteinuria was unlikely. Proteinuria was VCOG-
CTCAE grade III in one dog (dog-6) and either grade II or III 
in three.
Table 2. Clinical parameters for the dogs that were non-proteinuric at baseline that developed and did not develop 
proteinuria within the first 202 days of masitinib treatment and those with pre-treatment proteinuria
Parameter Non-proteinuric prior to masitinib treatment Proteinuric prior to masitinib 
treatment (n=6)Developed proteinuria (n=4) Did not develop proteinuria (n=18)
Sex 1 ME, 1 MN, 1 FE, 1 FN 3 ME, 5 MN, 0 FE, 10 FN 3 ME, 0 MN, 0 FE, 3 FN
Median age in years (range) 9.0 (4.3–11.1) 8.0 (4.5 to 12.2) 10.3 (4.6 to 13.6)
Breeds Jack Russell terrier (n=1), Dogue de 
Bordeaux (n=1), crossbreed (n=1), 
lurcher (n=1).
Labrador retriever (n=4), boxer (n=2), 
crossbreed (n=2), Jack Russell terrier 
(n=1), West Highland white terrier 
(n=1) golden retriever (n=1), French 
bulldog (n=1), Boston terrier (n=1), 
beagle (n=1), Doberman pincher 
(n=1), German pointer (n=1), springer 
spaniel (n=1), Weimaraner (n=1).
Labrador retriever (n=1), golden 
retriever (n=1), West Highland 
white terrier (n=1), Hungarian 
vizsla (n=1), crossbreed 
(n=1), bullmastiff (n=1)
Median weight in kg (range) 22.0 (8.0–54.0) 31.7 (6.0–39.0) 29.6 (14.2–64.4)
Tumour type 3 MCT, 1 EL 14 MCT, 2 EL, 1 vulva lymphoma, 1 MM 2 EL, 4 MCT
Number in which gross disease 
present at baseline
4 (100%) 15 (83%) 6 (100%)
Median number of days between 
diagnosis and starting masitinib 
(range)
108 (22 to 668) 56 (18 to 701) 107 (6 to 380)
Number which had received 
previous chemotherapy
2 (50%) 6 (33%) 5 (83%)
Median time since previous 
chemotherapy in days (range)
41 and 552 days 56 (12 to 217) 22 (15 to 69)
Number of dogs with co-morbidities 1 (25%) 6 (33%) 2 (33%)
Number of dogs receiving 
prednisolone at baseline
0 3 (17%) 4 (66%)
Median creatinine (μmol/L) at 
baseline (range) (reference range: 
45 to155)
100 (65 to 134) 86 (66 to 141) 96 (76 to 132)
Number of dogs with low albumin 
at baseline (reference range: 29 
to 36)
1 (25%) 1 (6%) 3 (50%)
Median albumin (mg/L) at baseline 
(range)
32 (25 to 37) 32 (24 to 38) 29 (23 to 30)
Number of dogs with USG ≥1.030 
at baseline
1 (33%)† 11 (61%) 1 (17%)
Median UP:C at baseline (range) 0.05 (0 to 0.45) 0.15 (0.02 to 0.20) 1.68 (0.66 to 4.40)
Median starting masitinib dose in 
mg/kg (range)
12.33 (11.10 to 13.60) 11.61 (9.70 to 12.50) 11.67 (5.70 to 12.70)‡
Median masitinib dose in mg/kg 
(range)
11.59 (10.98 to 12.82) 11.17 (6.30 to 12.40) 11.42 (4.21 to 12.71)
Median duration of masitinib 
treatment in days (range) [number 
censored§]
31 (18 to 202§) [1] 97 (15 to 202§) [6] 32 (34 to 60) [0]
Number of dogs on masitinib at end 
of study (day 202)
1 (25%) 6 (33%) 0
Median number of timepoints at 
which blood and urinalysis were 
available on masitinib per dog 
(range)
3 (1 to 5) 3 (1 to 5) 2 (1 to 3)
Median time of last UP:C on 
masitinib during the study (range)
38 (15 to 179) 82 (9 to 197) 29 (26 to 46)
ME Male entire, MN Male neutered, FE Female entire, FN Female neutered, MCT Mast cell tumour, CEL Cutaneous epitheliotropic lymphoma, MM Malignant melanoma, USG Urine specific 
gravity, UP:C Urine protein to creatinine ratio
†The urine specific gravity was not available for one dog in this group at baseline.
‡One dog (dog 23) was on less than 50% of the recommended starting dose of 12.5 mg/kg. The next lowest dose was 10.6 mg/kg.
§Data were available beyond 202 days but were right censored at this point if dogs were still on treatment as it was the end of the study
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When dog-4 developed proteinuria (UP:C 8.2) at T1, albumin 
and USG were unchanged (albumin at T0: 25 g/L; T1: 27 g/L 
and USG at T0: 1.012; T1: 1.015), but creatinine increased 
markedly (T0: 75 μmoL/L; T1: 108 μmoL/L). Ten days before 
T1 (but after T0), oral prednisolone (Prednidale; Dechra) had 
been started (0.45 mg/kg twice daily) and omeprazole (Omepra-
zole; Actavis) was stopped. Masitinib was discontinued when 
proteinuria was documented but prednisolone was continued at 
the same dose. One week later, the UP:C was 2.53, creatinine 
and albumin remained stable. Euthanasia occurred 2 weeks later 
due to disease progression.
In dog-6, albumin markedly declined (T0: 37 g/L; T1: 41 g/L; 
T2: 21 g/L) when proteinuria (UP:C 4.56) was detected at T2. 
Creatinine remained stable (T0: 135 μmoL/L; T1: 132 μmoL/L; 
T2: 135 μmoL/L). Masitinib was discontinued when proteinuria 
was identified. Four days later, the dog was lethargic, hyporexic 
and vomiting with evidence of MCT progression. The UP:C was 
15.0 and albumin was 13 g/L. Neither oedema nor ascites were 
documented. Creatinine had increased slightly (150 μmoL/L) but 
USG was unchanged (T0: >1.050; T1: 1.045; T2: >1.050). Sys-
tolic blood pressure was normal. Benazepril (Fortekor; Elanco), 
omeprazole (Omeprazole; Actavis), famotidine (Famotidine; Til-
lomed Laboratories), maropitant (Cerenia; Zoetis) and predniso-
lone (Prednidale; Dechra) (0.57 mg/kg once daily) were started. 
Eight days after masitinib discontinuation the dog was clinically 
well, UP:C was 2.92, albumin had increased (19 g/L) and cre-
atinine had reduced (125 μmoL/L). The dog was hypertensive 
(SBP 185 mmHg). Amlodipine (Amlodipine; Actavis) and fish 
oil (Megaderm; Virbac) were added. The dog was treated with 
a vinblastine/prednisolone protocol, benazepril, amlodipine and 
Table 3. Presence or absence of proteinuria at each timepoint and outcome in dogs without proteinuria at baseline
Dog Number T0  
(baseline)
T1  
(days 7 to 20)
T2  
(days 21 to 34)
T3  
(days 35 to 62)
T4  
(days 63 to 90)
T5  
(days 91 to 146)
T6  
(days 147 to 202)
1 NP NP Dead Dead Dead Dead Dead
2 NP NP Off masitinib Off masitinib Off masitinib Off masitinib Dead
3 NP NP Off masitinib Off masitinib Off masitinib Dead Dead
4 NP P Off masitinib Off masitinib Dead Dead Dead
5 NP NP NP Off masitinib Dead Dead Dead
6 NP NP† P Off masitinib Off masitinib Off masitinib Off masitinib
7 NP† Missing Missing NP Dead Dead Dead
8 NP P NP NP Off masitinib Dead Dead
9 NP NP Missing Missing Off masitinib Dead Dead
10 NP NP NP NP Missing Dead Dead
11 NP† NP NP NP NP Dead Dead
12 NP NP NP NP NP Off masitinib Off masitinib
13 NP NP Missing NP Missing Off masitinib Off masitinib
14 NP Missing NP NP Missing NP† Off masitinib
15 NP NP Missing NP Missing NP Off masitinib
16 NP NP Missing NP NP NP NP
17 NP NP NP Missing NP NP NP
18 NP NP NP Missing NP Missing NP
19 NP NP NP Missing NP NP Missing
20 NP† NP† NP† NP† Missing NP NP
21 NP P P P NP Missing NP
22 NP NP NP NP NP NP Missing
NP Non-proteinuric (UP:C < 0.5), P Proteinuric (UP:C ≥ 0.5)
T0 to T6 – timepoints
†Samples that did not have UP:C measured at our university reference laboratory.
Table 4. Co-morbidities and associated treatments
Dog number Co-morbidities Medication
Dogs without proteinuria 
at baseline
5 Atopy None
8 Diabetes mellitus Lente insulin (Caninsulin; MSD Animal Health)
9 Paw laceration Amoxicillin and clavulanic acid (Synulox; Zoetis)
11 Atopy Oclacitinib (Apoquel; Zoetis)
12 Arthritis, idiopathic epilepsy Glucosamines (Senoquin; VetPlus), phenobarbitone 
(Epiphen; Vetoquinol), firocoxib (Previcox; Boehringer 
Ingelheim)
16 Arthritis None
18 Mitral valve disease, pulmonary hypertension Pimobendan (Vetmedin; Boehringer Ingelheim)
19 Atopy Dexamethasone ear drops (Maxidex; Alcon), fusidic acid 
and betamethasone topical cream (Isaderm; Dechra) 
and hyposensitisation vaccine (Artuvetrin; Artuvet)
Dogs with proteinuria at 
baseline
23 Renal proteinuria, systemic hypertension 
(controlled), hypothyroidism (controlled), 
subaortic stenosis
Benazepril (Fortekor; Elanco), amlodipine (Istin; Pfizer) 
and levothyroxine (Thyforun; Dechra)
26 Idiopathic pulmonary fibrosis None
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fish oil. He was euthanised 10 months after starting masitinib, 
due to MCT progression. The dog remained proteinuric (UP:C 
0.92–3.31) throughout but albumin normalised, and creatinine 
remained normal.
Dog-8 had no change in albumin or creatinine when protein-
uria was detected at T1 (UP:C 1.27) (albumin T0: 32 g/L; T1: 
34 g/L and creatinine T0: 65 μmoL/L; T1: 67 μmoL/L). Masi-
tinib was continued and UP:C was subsequently normal on 2 
further occasions (day 26 and 45). Masitinib was discontinued 
after 47 days due to disease progression and she was euthanised 
for this reason 29 days later.
Dog-21 developed proteinuria from T1 to T3 (UP:C T0: 0.20; 
T1: 0.54, T2: 1.06, T3: 0.55) yet serum creatinine and albumin 
remained stable (creatinine T0: 125 μmoL/L; T1: 110 μmoL/L; 
T2: 117 μmoL/L; T3: 102 μmoL/L and albumin T0: 34 g/L; 
T1: 30 g/L; T2: 30 g/L; T3: 28 g/L)). Proteinuria resolved after 
T3 and never recurred despite the masitinib dose remaining 
unchanged. A herbal skin supplement (Pomi-T; Herbal medi-
cine) was started at T3. Masitinib was discontinued on day 1028. 
The dog was euthanised 7 days later due to cardiac disease.
Dogs with pre-treatment proteinuria (dogs 23–28)
Two dogs had EL and four had MCT. All dogs with MCT were 
receiving a histamine-1-receptor antagonist, two a histamine-
2-receptor antagonist and one a proton pump inhibitor. Two 
dogs had comorbidities (dog-23 and dog-26; Table 4) and dog-
28 was receiving S-adenosyl methionine (Samylin; VetPlus).
The median pre-treatment UP:C was 1.68 (range: 0.66–4.4). 
Proteinuria was classified as pathological renal in five dogs (3 
were receiving prednisolone). In the sixth (dog-24), proteinuria 
was classified as pathological renal or post-renal. Creatinine was 
within the reference interval in all dogs. Three dogs had low albu-
min (23 g/L, 27 g/L, 28 g/L) (RR: 29 and 36).
Effect of masitinib treatment
Median masitinib starting dose was 11.67 mg/kg (Table 2). Masi-
tinib treatment was discontinued due to lack of efficacy in three 
dogs, and three were euthanased on treatment, two for disease 
progression and one for an unknown reason. Gross disease was 
present in all dogs at all timepoints.
Median UP:Cs were 0.56, 0.56 and 0.29 at T1, T2 and T3, 
respectively (Fig. 2). Proteinuria was not categorised as pre-renal, 
physiological renal or post-renal, nor was creatinine increased 
above the RR in any dog at any timepoint after baseline.
In three dogs (dog-23, dog-24, dog-25), the UP:C magnitude 
declined at each visit despite starting treatment with masitinib 
(Table 5, Fig. 2). None of these dogs had reductions in serum 
albumin during treatment (albumin T0: 23 g/L, 30 g/L and 
28 g/L and minimum values: 22 g/L, 29 g/L, 28 g/L, respectively).
The three remaining dogs (dog-26, dog-27, dog-28) had 
UP:C fluctuations over time but none had increases of over 50%. 
In two dogs (dog-27 and dog-28), UP:C increases occurred when 
prednisolone doses were increased. Of these three dogs, one had a 
7-day masitinib drug holiday followed by an 11.3% dose reduc-
tion (due to neutropenia) and one (dog 28) had a 60% dose 






















FIG 1. Urine protein to creatinine ratio (UP:C) over time for dogs without 
proteinuria at baseline that became proteinuric. T0 to T6 – timepoints
FIG 2. Urine protein to creatinine ratio (UP:C) over time for dogs with proteinuria at baseline. T0 to T3 – timepoints
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albumin declined slightly over time (albumin T0: 30 g/L, 27 g/L 
and 29 g/L and minimum values 27 g/L, 24 g/L, 28 g/L).
DISCUSSION
Four (18.2%) out of 22 dogs that were non-proteinuric pre-
treatment developed proteinuria within 202 days of masitinib 
commencement. This is similar to the proteinuria incidence of 
16 and 23% previously described (Cadot et al. 2011, Smrkovski 
et al. 2015). All four of these dogs had developed proteinuria by 
day 31 (T2).
Little is known about which dogs are predisposed to develop-
ment of proteinuria with masitinib treatment. Hahn et al. (2008) 
suggested that pre-treatment azotaemia increased the likelihood 
of masitinib-associated renal disorders including proteinuria; 
however, none of the dogs in this study had pre-treatment azo-
taemia. Few dogs developed proteinuria, preventing us drawing 
any conclusions about other predisposing factors, however pre-
treatment urine specific gravity values were lower in those that 
developed proteinuria (Table 2). This warrants further investiga-
tion.
There is limited information about when proteinuria devel-
ops in masitinib treated dogs. Cadot et al.  (2011) suggested 
that in 202 dogs treated with masitinib, proteinuria tended to 
develop within 3 months of drug commencement, although 
no further details were given. Smrkovski et al.  (2015) reported 
that all adverse events (including proteinuria) occurred within 
6 months despite a median treatment time of 300 days. Protein-
uria was not identified for the first time in any dogs in this study 
after 31 days, despite being treated and monitored for a median 
of 87 days. Although in two reports of dogs developing severe 
protein losing nephropathies (PLN) on masitinib therapy, pro-
teinuria was not noted until 5 and 11 weeks following treatment 
starting, the first only had one urine dipstick test (showing trace 
protein) performed after 2 weeks and the latter had no earlier uri-
nalysis results reported on treatment (Sum et al. 2010; Devine & 
 Polzin 2016). Proteinuria may have been detected earlier in both 
cases had more frequent testing been performed. Our results sug-
gest proteinuria is more likely to develop within the first month 
of treatment, emphasising the importance of urine protein moni-
toring during this period.
Although proteinuria was detected within 16 days of masi-
tinib commencement in 3 dogs, the fourth (dog-6) was non-
proteinuric after 2 weeks but developed marked proteinuria and 
hypoalbuminaemia 2 weeks later. Similarly, in two reports of 
dogs developing PLN, early urine tests did not identify protein-
uria, but severe proteinuria was identified 2 to 3 weeks later (Sum 
et al. 2010, Brown et al. 2013). This demonstrates that a normal 
UP:C early in masitinib treatment does not preclude develop-
ment of severe proteinuria within the first month.
Proteinuria can be marked, with UP:C > 5 and concurrent 
severe hypoalbuminaemia (<12 g/L) reported in two dogs (Sum 
et al. 2010, Brown et al. 2013). Two dogs developed anuric acute 
renal failure (ARF) following development of proteinuria on 
treatment and were subsequently euthanased (Brown et al. 2013, 
Smrkovski et al.  2015). Studies that have monitored urinalysis 
and reported adverse effects in groups of mastinib-treated dogs 
reported limited information on proteinuria magnitudes and 
patient outcomes. In one study, proteinuria was categorised as 
severe (VCOG-CTCAE grade III) in 36.4% of 33 dogs that 
developed proteinuria (Cadot et al.  2011). It is unclear how 
many dogs developed hypoalbuminaemia or died as a result. 
Smrkovski et al.  (2015) reported that two dogs (33.3%) devel-
oped VCOG-CTCAE grade I, 3 (50%) VCOG-CTCAE grade 
II and 1 VCOG-CTCAE grade III proteinuria. In our study, 
the highest UP:C identified on treatment was 8.2; however, the 
UP:C continued to increase and hypoalbuminaemia developed 
shortly after treatment discontinuation. Of the other three dogs 
that developed proteinuria, UP:C exceeded 2.0 in only one and 
none developed hypoalbuminaemia. Overall, none of the dogs 
developed ascites or oedema, azotaemia or were euthanased 
because of proteinuria; however, UP:Cs were closely monitored, 
and treatment stopped when UP:C > 2.0. Although proteinuria 
can be severe and cause fatal complications, this appears to be 
relatively rare, particularly with frequent monitoring and prompt 
action should it occur.
When proteinuria is detected in a dog receiving masitinib, 
decisions must be made as to what action is taken. The data-
sheet recommends monthly urine dipstick and albumin moni-
toring, and further testing (including UP:C, creatinine and 
albumin) if urine protein exceeds 30 mg/dl (AB Science 2009). 
Temporary treatment discontinuation is advised if UP:C > 2.0 
(AB Science 2009). In another reported protocol treatment was 
discontinued if VCOG-CTAE grade III proteinuria (UPC > 1.0 
for ≥14 days) was identified (Hahn et al.  (2008); Smrkovski 
et al. (2015)). Although temporary or permanent masitinib dis-
continuation is safest to reduce the risk of development of severe 
PLN, this must be considered against the reason for drug admin-
istration in dogs with potentially life-limiting neoplastic disease.
Table 5. Presence or absence of proteinuria at each timepoint and outcome in dogs with proteinuria at baseline
Dog Number T0  
(baseline)
T1  
(days 7 to 20)
T2  
(days 21 to 34)
T3  
(days 35 to 62)
T4  
(days 63 to 90)
T5  
(days 91 to 146)
T6  
(days 147 to 202)
23 P Missing P Off masitinib Off masitinib Off masitinib Off masitinib
24 P P NP NP Off masitinib Off masitinib Off masitinib
25 P Missing NP Dead Dead Dead Dead
26 P P NP Off masitinib Off masitinib Dead Dead
27 P NP Missing NP Dead Dead Dead
28 P NP P Missing Dead Dead Dead
NP Non-proteinuric (UP:C < 0.5), P Proteinuric (UP:C ≥ 0.5)
T0 to T6 – timepoints
M. Kuijlaars et al.
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Various post-renal causes have been reported to increase UP:C 
to greater than 1.0 and greater than 2.0 (Bagley et al. 1991, Vaden 
et al. 2004, Jillings et al. 2019). We attempted to retrospectively 
identify the origin of proteinuria. In two dogs, we could not 
exclude a post-renal origin of proteinuria. Despite ongoing masi-
tinib treatment in dog-8, UP:C normalised (1.27 to 0.16), pos-
sibly due to resolution of post-renal proteinuria. In dog-4, UP:C 
reduced (8.2 to 2.5) but remained greater than 0.5 one week 
later despite masitinib discontinuation. Following identification 
of proteinuria less than 2.0 in dogs receiving masitinib, investiga-
tions (including collection of a cystocentesis sample [to confirm 
persistence and exclude reproductive disease], urine sediment 
examination and urine culture [to exclude post-renal proteinuria] 
and haematology and biochemistry profiles [to exclude pre-renal 
proteinuria]) should be performed to try and exclude non-renal 
or physiological causes, unrelated to masitinib administration. 
If these are identified, institution of appropriate treatment may 
avoid the need for masitinib therapy interruption.
If renal proteinuria is still suspected, a decision must be made 
whether to discontinue therapy. Patient outcomes when masi-
tinib has been continued despite the development of proteinuria 
have been variable. In the report by Brown et al. (2013), masi-
tinib was continued despite the detection of proteinuria (UP:C 
0.6) and 2 weeks later severe proteinuria (UP:C 20.8) and con-
current severe hypoalbuminaemia occurred. Treatment was then 
discontinued but anuric ARF developed and the dog euthanased 
within 3 days. However, in the study by Smrkovski et al. (2015) 
in which monthly urine monitoring was performed, five dogs 
receiving masitinib developed low magnitude proteinuria (0.5–
1.0) or UPC greater than 1.0 for less than 14 days. In those cases, 
treatment was continued but neither grade III proteinuria nor 
serious complications occurred. Similarly, in this study, both dogs 
which developed UP:Cs between 1.0 and 2.0 did not develop 
significant worsening of UP:C, hypoalbuminaemia or azotaemia 
despite continued masitinib treatment. In both, UP:C was nor-
mal 13 and 75 days later and remained so throughout treatment 
(a further 20 and 939 days). This suggests some dogs developing 
UP:C 0.5–2.0 progress to severe disease and others do not. As we 
cannot predict which cases will progress and because proteinuria 
can progress rapidly, if treatment is continued despite low magni-
tude proteinuria development, repeat monitoring should be per-
formed within 1 week enabling rapid treatment discontinuation 
if UP:C exceeds 2.0.
Despite masitinib discontinuation, proteinuria can continue 
to progress rapidly, hypoalbuminaemia and azotaemia may 
develop or worsen. In one of two dogs (dog-6) with UP:C > 2.0, 
UP:C worsened markedly (4.56 to 15) and serum albumin fell 
dramatically (21 to 13 g/L) within 4 days following treatment 
discontinuation before improving 4 days later. Similarly, in 
the reports by Sum et al.  (2010) and Devine & Polzin  (2016) 
in which masitinib was discontinued within 2 days of protein-
uria or hypoalbuminaemia documentation, initial worsening of 
hypoalbuminaemia and/or azotaemia or UP:C occurred prior 
to improvement. In both cases, complete recovery (except an 
ongoing UP:C elevation in 1 dog) occurred without long-term 
ill effects (Sum et al. 2010, Devine & Polzin 2016). Not all dogs 
recover after treatment discontinuation (Smrkovski et al. 2015). 
Recovery can take 1  month and can have negative effects on 
quality of life and be expensive (Devine & Polzin 2016). Ear-
lier detection and treatment discontinuation appear to lead to 
quicker recovery, with patients with asymptomatic proteinuria 
recovering faster than those with clinical signs or sequelae (Sum 
et al. 2010, Devine & Polzin 2016). This supports frequent, pos-
sibly weekly, monitoring of UP:C for at least the first month of 
treatment to allow early discontinuation and make a rapid recov-
ery more likely.
According to the masitinib datasheet, its use is contraindicated 
in dogs with a pre-treatment UP:C > 2.0 (AB Science 2009). The 
large studies reporting masitinib treatment do not report pre-
treatment UP:C, nor do they specify criteria for exclusion based 
on pre-treatment UP:C (Hahn et al.  2008, Cadot et al.  2011, 
Smrkovski et al. 2015, Grant et al. 2016). The effect of masitinib 
administration to dogs with pre-existing proteinuria has not been 
reported.
Fifteen percent of dogs presented to an oncology service had 
a UP:C greater than 0.5, and prednisolone, which is commonly 
administered to patients with neoplasia, can cause proteinuria 
(Waters et al.  1997, Prudic et al.  2018). Some dogs in which 
masitinib treatment may be considered will therefore have pre-
treatment proteinuria. We report the renal effects of masitinib 
therapy in six dogs with pre-treatment proteinuria (median 
UP:C 1.68). Two dogs had a pre-treatment UP:C > 2.0. Over-
all, 21% had pre-treatment proteinuria which is similar to the 
previously reported incidence (Prudic et al.  (2018)). In five 
of six dogs pathological renal proteinuria was considered the 
likely cause. The median time between diagnosis and treatment 
commencement of 106.5 days and that five of six dogs had had 
prior treatment suggests that masitinib was selected when other 
treatment modalities had been exhausted. Masitinib therapy 
was initiated within the recommended dose range in five of six 
patients.
In three dogs (including the dog with possible post-renal pro-
teinuria), proteinuria decreased at each subsequent measurement 
despite masitinib treatment. In the other three, UP:C increases 
were only present at one timepoint and were all <50%. In two 
of three dogs with UP:C increases, prednisolone was added, or 
the dose increased and the masitinib dose reduced at the previ-
ous visit suggesting masitinib treatment was not the likely cause. 
No dogs had masitinib stopped due to proteinuria, nor did any 
develop hypoalbuminaemia or azotaemia. Although, treatment 
duration was short (median 32 days), proteinuria developed 
within 1 month in the non-proteinuric dogs so severe worsen-
ing of proteinuria might also be expected in proteinuric patients 
within this timeframe. This suggests masitinib treatment in dogs 
with pre-existing proteinuria might be safe, even if a renal ori-
gin cannot be excluded. The number of dogs described is small, 
most dogs had pre-treatment UP:C less than 2.0 and the origin 
of proteinuria was unknown, but further investigation of mas-
itinib treatment in a larger group of dogs with pre-treatment 
proteinuria, with longer treatment duration and follow-up, is 
warranted to enable the safety of its use in these patients to be 
further evaluated.
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This study has certain limitations, including small case num-
bers, variety of tumours, variable masitinib doses (including sig-
nificant dose reductions in some patients due to other toxicities) 
and concurrent drugs administered. In addition, its retrospec-
tive nature resulted in missing data points, no control group, 
unknown locations of urine sample collection and unconfirmed 
origins of proteinuria (due to infrequent urine cultures and 
absence of renal biopsies). More rigorous exclusion of post-renal 
causes would have been desirable. Routine SBP monitoring was 
not performed so no comment can be made on the role of hyper-
tension in proteinuria development.
A larger, prospective study of dogs receiving masitinib treat-
ment, including a control population, and in which patients are 
followed up for longer is now warranted. Patients developing 
proteinuria should be rigorously investigated to exclude non-
renal causes. This should allow the timing of and reasons for 
development of proteinuria to be confirmed and allow recom-
mendations on the monitoring of proteinuria in these patients 
to be optimised.
The use of masitinib in dogs in this study was off-licence as 
C-KIT MCT expression was not determined and many dogs 
were treated for other tumours.
In this study, the reported incidence of proteinuria with masi-
tinib treatment was similar to that previously reported. Protein-
uria only developed within the first month of treatment. Severe 
proteinuria (UPC > 2.0) was identified in two of four dogs that 
developed proteinuria. Despite rapid treatment discontinuation 
in both, proteinuria continued to worsen in one dog prior to 
UP:C improvement and resolution of sequelae. Weekly UP:C 
monitoring for the first month of treatment is recommended to 
facilitate rapid treatment discontinuation when UP:C exceeds 
2.0. Development of mild proteinuria (UP:C < 2.0) may not 
require treatment discontinuation but investigation of its origin 
and repeat testing within 1 week is recommended.
An additional finding was that significant worsening of pro-
teinuria and development of sequelae did not occur in any of the 
six dogs with pre-treatment proteinuria; however, further investi-
gation treating these patients is now needed.
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